In this session recorded at DPHARM 2022, moderated by Pfizer's Amy Cramer, the panelists discuss patient data.

Often the elephant in the room that hinders the advancement of innovation in clinical trials for the benefit of patients in the lack of structured, clean patient data. R&D executives know the ability to garner greater data value from all data sources [clinical trials, EHRs, claims data, etc] is critical to supporting the future of drug development. The continued conundrum is that data is too often unstructured, incompatible, incomplete and unreliable and leads to an output of a research-intensive, operational bottlenecks.

We have a unique group of panelists who will prioritize the critical issues first, provide potential solutions and address what to do about pending issues to be resolved.

Speakers:

Amy Cramer, Global Product Development Strategic Partnerships, Pfizer
Xiaoying Wu, MD, MS, VP, Data Science Data Platform & Privacy, The Janssen Pharmaceutical Companies of Johnson & Johnson
Paul Bleicher, MD, PhD, Executive Partner, Arden Equity
Lekan Wang, Head, Machine Learning Services, Parexel

Addressing the Lack of Structured, Clean Patient Data

Share

Embed